GLP-1 Competitive Market — July 17, 2026
|
Novo Nordisk’s European Commission approval of oral Wegovy hands it the continent’s first obesity pill and a 12-to-18-month clear runway before Lilly’s orforglipron arrives in 2027 — shifting the GLP-1 battleground from the needle to the tablet.
Today’s top developments:
|
What to Watch
- Lilly’s EU orforglipron filing — A European filing announcement within six months would compress the oral-obesity competitive clock that Novo’s Wegovy approval just started.
- ADA governance fallout — The board’s handling of the Diabetes Care editorial-suppression row will decide whether the journal keeps its guideline-anchoring role ahead of the 2027 GLP-1 expansion into CKD and MASH.
- Vogenx SGLT1 readout — Phase 2 enrollment pace and readout timing will test whether non-GLP-1 metabolic IPOs can hold investor interest through a crowded 2026–2027 biotech calendar.
- Novo’s tolerability play — Completion of the NNC0662-0419 dose-escalation study will signal whether Novo can close the tolerability gap with tirzepatide that drives real-world retention.
This brief highlights the edition’s top stories. Read the full July 17, 2026 edition → for all stories and analysis — or browse the GLP-1 Competitive Market archive.